Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a rare disease with an unknown etiology which most commonly results in subacute diplopia and ataxia. Diagnosis is achieved through a triad of the following findings: lymphocytic pleocytosis with increased CD4+ T cells on cerebrospinal fluid (CSF) analysis; perivascular punctate and curvilinear hemorrhages in the pons, medulla, or cerebellum on magnetic resonance imaging (MRI) with contrast; and the cessation of symptoms after the initiation of corticosteroids. Here, we report the case of a 23-year-old male who presented with non-specific signs and symptoms, including diffuse weakness in all limbs, ataxia, and slurred speech. The diagnosis was achieved through a contrast MRI of the brain, suggestive of brainstem encephalitis, and a CSF analysis, which revealed elevated glucose and protein levels. Intravenous methylprednisolone was administered for five days and resulted in acute improvement of the patient's clinical status. Repeat CSF analysis and MRI of the brain with contrast two weeks later showed resolution of previous findings. CLIPPERS syndrome is a newly identified disease thought to cause a predominantly inflammatory reaction in the pons, medulla, cerebellum, and supratentorial region. MRI with contrast tends to reveal a "salt and pepper appearance" in a punctate and curvilinear fashion. The hallmark of treatment is corticosteroid therapy, and discontinuation of therapy should be done with caution as relapse of the syndrome with corticosteroid withdrawal has been documented.

Cancer and diabetes are critical risks that reveal many complications. Metformin has long been used in herbal medicine as an anti-diabetes medicine. It is one of the first-line therapies for type two (T2D that has gained use across different healthcare systems. It is the most preferred form of treatment due to its safety, being readily available, and widely used because it has fewer and affordable side effects for many users. The repurposing of metformin used in other treatments to treat cancer patients or the combination of targeted treatments with metformin can reduce the side effects of chemotherapy drugs, enhance the effectiveness, and may reduce resistance to targeted drugs. The mechanism of metformin has been demonstrated and its association with other drugs. It Inhibits cell growth and stops the cell cycle, and stimulates programmed cell death and autophagy of various cancer cells. Patients with diabetes and different kinds of malignancies such as colorectal, hepatic, and ovarian cancers have better response rates after metformin treatment. A combination of metformin and new medications has had a significant effect on those who do not receive metformin. On the other hand, prevailing evidence has greatly proved the benefit of using metformin as an adjuvant agent in medical oncology practice.